AML Detection Screen Using CD34 CD45RA CD90 CD123 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML) are inadequate, with real-time quantitative PCR not possible in half of patients and multi-parameter flow cytometry lacking clinical utility due to sensitivity issues.
Innovation Solution
A diagnostic screen utilizing specific cell surface polypeptide markers such as CD34+, CD45RA+, and CD90−/CD123+ for detecting AML, employing antibodies to confirm the presence or absence of these markers in blood cell samples, enhancing diagnostic and prognostic capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If real-time quantitative PCR is used for MRD detection, then sensitivity is improved, but it cannot be applied to approximately half of AML patients
Solution Approach 1:
The invention changes the detection parameters from genetic mutations (PCR target) to cell surface protein markers (flow cytometry target). This parameter change allows the detection method to be applicable to all AML patients regardless of mutation status, while maintaining high sensitivity through the specific marker combination of CD34+, CD45RA+, and CD90−/CD123+
2Adaptability or versatility
If multi-parameter flow cytometry is used for MRD detection, then patient applicability is improved, but sensitivity is at least 1 log below real-time PCR
Solution Approach 1:
The invention applies local quality by focusing flow cytometry detection on specific cell populations with distinct marker profiles. By defining precise phenotypic characteristics (CD34+ CD45RA+ CD90− CD123+), the method achieves high sensitivity within the target population while maintaining broad patient applicability through universal marker expression
Solution Approach 2:
The invention changes the detection approach from looking for absent mutations (PCR) to detecting present abnormal marker expressions (flow cytometry). This parameter inversion allows flow cytometry to achieve sensitivity comparable to or exceeding PCR in certain contexts, while being universally applicable to all AML patients
3Ease of operation
If conventional flow cytometry with standard CD markers is used, then ease of operation is maintained, but diagnostic precision for AML subtypes is insufficient
Solution Approach 1:
The invention uses a composite marker profile approach, combining multiple CD markers (CD34, CD45RA, CD90, CD123) to create a comprehensive diagnostic signature. This composite approach maintains the ease of flow cytometry operation while significantly improving diagnostic precision for AML subtype classification and MRD detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed screen provides a robust diagnostic and prognostic tool for AML, improving the detection and monitoring of MRD, thereby aiding in patient management and treatment efficacy assessment.
Implementation Method 1
a diagnostic antibody (labelled with a fluorophore) is employed, which binds to a surface molecule (e.g. a CD molecule) present on and characteristic of the cell population in question
Implementation Method 2
Flow cytometry is a technique for counting and examining microscopic particles such as cells by suspending them in a stream of fluid and capturing the light that emerges from each cell as it passes through a laser beam
Implementation Method 3
capturing the light that emerges from each cell as it passes through a laser beam
Implementation Method 4
the flourophore (attached to the antibody) is activated by a laser beam and the fluorescence signal detected by the flow cytometer
Data Source
AI summary
The present invention relates to diagnostic screens, antibodies, methods and kits for detection/prognosis of acute myeloid leukaemia. The diagnostic screen detects the presence (+) or absence (−) of the cell surface polypeptide markers i) CD34+; ii) CD45RA+; and iii) CD90− and/or CD123+. Antibodies specific for one or more of said cell surface polypeptide markers may be used in the diagnostic screen of the invention. Diagnostic and prognostic methods for detecting and monitoring minimal residual disease based on said screen also form part of the invention.